I-Mab Biopharma

The momentum for this stock is not very good. I-Mab Biopharma is not a good value stock. I-Mab Biopharma is not a good growth stock. I-Mab Biopharma is not very popular among insiders. I-Mab Biopharma is a mediocre stock to choose.

News

I-Mab's uliledlimab shows positive pharmacokinetics data in lung cancer

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

PR Newswire I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer PR...\n more…

I-MAB Engages Interim CEO in Strategic Agreement

TipRanks Financial Blog I-MAB (IMAB) has released an update. I-MAB Biopharma US Limited has entered into a six-month secondment agreement with ABio-X Holdings, Inc., effective July 15, 202...\n more…

I-Mab First Half 2024 Earnings: US$0.19 loss per share (vs US$1.32 loss in 1H 2023)

Simply Wall St I-Mab ( NASDAQ:IMAB ) First Half 2024 Results Key Financial Results Net loss: US$15.7m (loss narrowed by 86% from 1H...\n more…

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

PR Newswire I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates PR Newswire ROCKVILLE, Md., Aug. 28...\n more…

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

PR Newswire I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire ROCKVILLE, Md...\n more…